SCHEMBL1663160

SCHEMBL1663160

CC(C)c1nc2cc(O)ccc2c(=O)n1-c1cccc2cccnc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.53
ALDH1A1 P00352 5/20 0.44
ESR1 P03372 3/20 0.43
ESR2 Q92731 3/20 0.43
GAA P10253 3/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.36
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663953 0.84 TRPV1 (0.57) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1664223 0.80 TRPV1 (0.55) TRPV1ALDH1A1ESR1ESR2MAPT
SCHEMBL1664030 0.79 TRPV1 (0.57) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1663889 0.79 TRPV1 (0.57) TRPV1ALDH1A1ESR1ESR2MAPT
SCHEMBL23273575 0.76 TRPV1 (0.65) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1665874 0.76 TRPV1 (0.54) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1665294 0.75 TRPV1 (0.70) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1664648 0.74 TRPV1 (0.56) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1663738 0.74 TRPV1 (0.65) TRPV1ALDH1A1ESR1ESR2GAA
SCHEMBL1663899 0.73 TRPV1 (0.60) TRPV1ALDH1A1ESR1ESR2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ALDH1A1 2499/4885ESR1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.